文献速递血栓与止血白血病

接受化疗的儿童急性淋巴细胞白血病患者中的静脉血栓栓塞:危险因素及血栓预防的有效性——LAL-SEHOP-PETHEMA-2013研究结果

Venous thromboembolism in pediatric patients with acute lymphoblastic leukemia under chemotherapy treatment. Risk factors and usefulness of thromboprophylaxis. Results of LAL-SEHOP-PETHEMA-2013.
PubMed 文献 · J Thromb Haemost · 2022-03-27

该回顾性多中心研究纳入652例1-18岁接受SEHOP-PETHEMA-2013方案治疗的急性淋巴细胞白血病(ALL)患儿,评估静脉血栓栓塞(VTE)发生率、抗凝治疗、结局、危险因素及低分子量肝素(LMWH)作为原发性血栓预防的安全性和有效性。VTE发生率为8.7%,多数发生在诱导治疗期间且与中心静脉导管相关。单因素分析显示家族血栓史、纵隔肿块、高危治疗组和遗传性易栓症为有统计学意义的危险因素。LMWH给药似乎降低了遗传性易栓症患者和T细胞ALL表型患者的VTE发生率。

要点

  • 652例ALL患儿中VTE发生率为8.7%,多数发生于诱导治疗期且与中心静脉导管相关。
  • 家族血栓史、纵隔肿块、高危治疗组和遗传性易栓症为有统计学意义的VTE危险因素。
  • LMWH给药似乎降低遗传性易栓症患者和T细胞ALL表型患者的VTE发生率。

核心结论

  • 多数VTE病例发生于无遗传性易栓症的患者,但存在遗传性易栓症时VTE风险更高。
  • LMWH给药有助于降低这些患者的VTE。

研究设计与样本

  • 回顾性多中心研究,纳入652例1-18岁接受SEHOP-PETHEMA-2013治疗方案指南的ALL患者,评估VTE发生率、抗凝治疗、结局、危险因素及LMWH作为原发性血栓预防的安全性和有效性。

主要发现

  • VTE发生率为8.7%。
  • 多数VTE病例发生于诱导治疗期间,与中心静脉导管相关。
  • 单因素分析显示家族血栓史、纵隔肿块、高危治疗组和遗传性易栓症为有统计学意义的危险因素。
  • LMWH给药似乎降低遗传性易栓症患者和T细胞ALL表型患者的VTE发生率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Symptomatic venous thromboembolism (VTE) is diagnosed in 3%-14% of patients during pediatric acute lymphoblastic leukemia (ALL) therapy. There are well-known risk factors, but the role of others as inherited thrombophilia is still controversial. Prophylaxis with low molecular weight heparin (LMWH) has been described, but its use is not globally accepted. METHODS: A retrospective multicentric study in ALL patients 1-18 years old following SEHOP-PETHEMA-2013 treatment guideline was performed to evaluate VTE rate, anticoagulant treatment, outcome, risk factors, and safety and usefulness of LMWH administration as primary thromboprophylaxis in children with inherited thrombophilia. RESULTS: A total of 652 patients were included in the study. VTE incidence was 8.7%. Most of the cases occurred during induction therapy associated with central venous catheter. Univariant analysis showed that family history of thrombosis, presence of mediastinal mass, high-risk treatment group, and inherited thrombophilia were statistically significant risk factors. LMWH administration seemed to decrease VTE rate in patients with inherited thrombophilia and those with T-cell ALL phenotype. CONCLUSION: Most of the VTE cases occurred in patients without inherited thrombophilia, but when it is present, the VTE risk is higher. LMWH administration was useful to decrease VTE in these patients.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Ruiz-Llobet A, Gassiot S, Sarrate E, et al. Venous thromboembolism in pediatric patients with acute lymphoblastic leukemia under chemotherapy treatment. Risk factors and usefulness of thromboprophylaxis. Results of LAL-SEHOP-PETHEMA-2013. J Thromb Haemost. 2022. PMID: 35289066. doi:10.1111/jth.15699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。